Oxaliplatin-induced severe anaphylactic reactions in metastatic colorectal cancer: Case series analysis

World Journal of Gastroenterology

Volumn 18, Issue 38, 2012, Pages 5427-5433

  Wang, Jui Ho ^a   King, Tai Ming ^a   Chang, Min Chi ^a   Hsu, Chao Wen ^a,b  

^a KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Anaphylactic; Colorectal cancer; Metastasis; Oxaliplatin

Indexed keywords

DIPHENHYDRAMINE; FLUOROURACIL; FOLINIC ACID; HYDROCORTISONE; OXALIPLATIN; SEROTONIN 3 ANTAGONIST;

ABDOMINAL PAIN; ADULT; AGED; AGITATION; ANAPHYLACTIC SHOCK; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD PRESSURE; BRONCHOSPASM; CANCER CHEMOTHERAPY; CHEST TIGHTNESS; CHILL; CLINICAL ARTICLE; COLORECTAL CANCER; CONSCIOUSNESS DISORDER; DIARRHEA; DYSPNEA; EDEMA; ERYTHEMA; FEMALE; FEVER; FLUSHING; HEADACHE; HEART PALPITATION; HEMOLYSIS; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; HYPOKALEMIA; HYPOTENSION; LARYNX SPASM; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; OXYGEN DESATURATION; PANCYTOPENIA; PRECORDIAL PAIN; REPEATED DRUG DOSE; RESPIRATORY DISTRESS; RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; SWEATING; SYSTEMATIC REVIEW; TACHYCARDIA; THROMBOCYTOPENIA; VISUAL DISORDER; VOMITING; WHEEZING;

EID: 84873732320     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v18.i38.5427     Document Type: Review

References (43)

1. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351
2. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Lévi F. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136-147
3. Culy CR, Clemett D, Wiseman LR. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs 2000; 60: 895-924
4. Saif MW. Hypersensitivity reactions associated with oxaliplatin. Expert Opin Drug Saf 2006; 5: 687-694
5. Grothey A, Hart LL, Rowland KM, Ansari RH, Alberts SR, Chowhan NM, Shpilsky A, Hochster HS. Intermittent oxaliplatin administration and time-to-treatment failure in metastatic colorectal cancer: Final results of the phase III CONcePT trial. J Clin Oncol 2008; 26 (Suppl): Abstract 4010 Available from: URL: http://www.asco.org/ascov2/Meetings/ Abstracts?&vmview=abst_detail_view&confID=55&ab stractID=34113
6. James E, Podoltsev N, Salehi E, Curtis BR, Saif MW. Oxaliplatin-induced immune thrombocytopenia: another cumulative dose-dependent side effect? Clin Colorectal Cancer 2009; 8: 220-224
7. Bautista MA, Stevens WT, Chen CS, Curtis BR, Aster RH, Hsueh CT. Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature. J Hematol Oncol 2010; 3: 12
8. Siu SW, Chan RT, Au GK. Hypersensitivity reactions to oxaliplatin: experience in a single institute. Ann Oncol 2006; 17: 259-261
9. Chay WY, Chew L, Yeoh TT, Tan MH. An association between transient hypokalemia and severe acute oxaliplatinrelated toxicity predominantly in women. Acta Oncol 2010; 49: 515-517
10. de Gramont A, Vignoud J, Tournigand C, Louvet C, André T, Varette C, Raymond E, Moreau S, Le Bail N, Krulik M. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997; 33: 214-219
11. Tournigand C, Maindrault-Goebel F, Louvet C, de Gramont A, Krulik M. Severe anaphylactic reactions to oxaliplatin. Eur J Cancer 1998; 34: 1297-1298
12. Larzillière I, Brandissou S, Breton P, Lingoungou A, Gargot D, Ramain JP, Harnois C. Anaphylactic reaction to oxaliplatin: a case report. Am J Gastroenterol 1999; 94: 3387-3388
13. Médioni J, Coulon MA, Morere JF, Hennebelle F, Piperno-Neumann S, Breau JL. Anaphylaxis after oxaliplatin. Ann Oncol 1999; 10: 610
14. Sørbye H, Bruserud Y, Dahl O. Oxaliplatin-induced haematological emergency with an immediate severe thrombocytopenia and haemolysis. Acta Oncol 2001; 40: 882-883
15. Santini D, Tonini G, Salerno A, Vincenzi B, Patti G, Battistoni F, Dicuonzo G, Labianca R. Idiosyncratic reaction after oxaliplatin infusion. Ann Oncol 2001; 12: 132-133
16. Schüll B, Kornek GV, Scheithauer W. Idiosyncratic reaction after oxaliplatin: circumvention by use of a continuous infusional administration schedule. Ann Oncol 2001; 12: 1653-1654
17. Brandi G, Pantaleo MA, Galli C, Falcone A, Antonuzzo A, Mordenti P, Di Marco MC, Biasco G. Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer 2003; 89: 477-481
18. Thomas RR, Quinn MG, Schuler B, Grem JL. Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer 2003; 97: 2301-2307
19. Lenz G, Hacker UT, Kern W, Schalhorn A, Hiddemann W. Adverse reactions to oxaliplatin: a retrospective study of 25 patients treated in one institution. Anticancer Drugs 2003; 14: 731-733
20. Bhargava P, Gammon D, McCormick MJ. Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer 2004; 100: 211-212
21. González-Mahave I, Lobera Iabairu T, Blasco Sarramián A, del Pozo Gil MD, Zorrilla M, Vélez de Mendizábal E. Anaphylaxis produced by oxaliplatin. J Investig Allergol Clin Immunol 2005; 15: 75-77
22. Maindrault-Goebel F, André T, Tournigand C, Louvet C, Perez-Staub N, Zeghib N, De Gramont A. Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients. Eur J Cancer 2005; 41: 2262-2267
23. Tze CNV. Anaphylactic shock to oxaliplatin in the adjuvant context. J Pharm Technol 2006; 22: 221-225
24. Lee MY, Yang MH, Liu JH, Yen CC, Lin PC, Teng HW, Wang WS, Chiou TJ, Chen PM. Severe anaphylactic reactions in patients receiving oxaliplatin therapy: a rare but potentially fatal complication. Support Care Cancer 2007; 15: 89-93
25. Yanqi C. Anaphylactic shock attributed to oxaliplatin use. Adverse Drug React J 2007; 9: 287
26. Santodirocco M, Lombardi V, Fesce C, Palumbo G, Capalbo S, Landriscina M. Life-threatening oxaliplatin-induced acute thrombocytopenia, hemolysis and bleeding: a case report. Acta Oncol 2008; 47: 1602-1604
27. Shao YY, Hong RL. Fatal thrombocytopenia after oxaliplatin-based chemotherapy. Anticancer Res 2008; 28: 3115-3117
28. Pietrantonio F, Di Bartolomeo M, Buzzoni R, Bajetta E. Acute immune-mediated thrombocytopenia due to oxaliplatin administration: a case report. Tumori 2010; 96: 154-156
29. Potenza S, Nasti G, Ottaiano A, Filippelli A, Rossi F, Capuano A. Severe respiratory symptoms to oxaliplatin infusion: a case report of delayed hypersensitivity reaction. Invest New Drugs 2010; 28: 185-186
30. Teng CJ, Hsieh YY, Chen KW, Chao TC, Tzeng CH, Wang WS. Sudden-onset pancytopenia with intracranial hemorrhage after oxaliplatin treatment: a case report and literature review. Jpn J Clin Oncol 2011; 41: 125-129
31. Misset JL. Oxaliplatin in practice. Br J Cancer 1998; 77 Suppl 4: 4-7
32. Curtis BR, Kaliszewski J, Marques MB, Saif MW, Nabelle L, Blank J, McFarland JG, Aster RH. Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin. Am J Hematol 2006; 81: 193-198
33. Koutras AK, Makatsoris T, Paliogianni F, Kopsida G, Onyenadum A, Gogos CA, Mouzaki A, Kalofonos HP. Oxaliplatin-induced acute-onset thrombocytopenia, hemorrhage and hemolysis. Oncology 2004; 67: 179-182
34. Watts SW. 5-HT in systemic hypertension: foe, friend or fantasy? Clin Sci (Lond) 2005; 108: 399-412
35. Kagiava A, Tsingotjidou A, Emmanouilides C, Theophilidis G. The effects of oxaliplatin, an anticancer drug, on potassium channels of the peripheral myelinated nerve fibres of the adult rat. Neurotoxicology 2008; 29: 1100-1106
36. Tan MH, Chay WY, Ng JH, Teh BT, Chew L. Transient bilateral abducens neuropathy with post-tetanic facilitation and acute hypokalemia associated with oxaliplatin: a case report. J Med Case Rep 2010; 4: 36
37. Kuwabara S, Kanai K, Sung JY, Ogawara K, Hattori T, Burke D, Bostock H. Axonal hyperpolarization associated with acute hypokalemia: multiple excitability measurements as indicators of the membrane potential of human axons. Muscle Nerve 2002; 26: 283-287
38. Stahl M, Köster W, Wilke H. Reaction after oxaliplatin--prevention with corticosteroids? Ann Oncol 2001; 12: 874
39. Siu SW, Chan WL, Liu KY, Choy TS, Leung TW, Au KH. Re-challenging patients with oxaliplatin allergy: the successful use of a standardised pre-medication protocol in a single institute. Clin Oncol (R Coll Radiol) 2011; 23: 558-559
40. Fontão-Wendel R, Hoff PM, Lazar A, Freitas D, Novis Y, Patah P, Tsujita M, Balthazar A, Pierroti M, Wendel S. Immunemediated pancytopenia induced by oxaliplatin: a case report. Transfusion 2010; 50: 1453-1459
41. Seki K, Senzaki K, Tsuduki Y, Ioroi T, Fujii M, Yamauchi H, Shiraishi Y, Nakata I, Nishiguchi K, Matsubayashi T, Takakubo Y, Okamura N, Yamamori M, Tamura T, Sakaeda T. Risk factors for oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer. Int J Med Sci 2011; 8: 210-215
42. Schwartzberg LS, Stepanski EJ, Fortner BV, Houts AC. Retrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices: assessment of clinical consequences. Support Care Cancer 2008; 16: 393-398
43. http: //www.ehealthme.com/ds/avastin/anaphylactic shock.